Study medicine INCB000928 for fibrodysplasia ossificans progressiva
Part of Bones, joints & muscles clinical trials.
This Phase 2 study tests whether INCB000928 can safely help people with fibrodysplasia ossificans progressiva (FOP). It mainly looks at whether the treatment is effective and well-tolerated, and it involves scheduled whole-body scans using low-dose X-rays.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed clinical diagnosis of FOP.
- Your age fits one of these groups: 12+ years, or 6 to under 12 years, or 2 to under 12 years (with additional safety review for younger kids).
- You can and are willing to avoid pregnancy (if you can become pregnant) or fathering a child during the study period, using the study’s rules for contraception.
- You can complete low-dose whole-body CT scan imaging (not including the head) without needing a breathing tube (intubation).
- You are not pregnant and not breastfeeding.
- You do not have CAJIS score 24 or higher, and your FOP severity does not make the study too risky or not possible for you.
- You do not currently have an active infection needing prescription antiviral/antifungal/antibiotic treatment, and you are not living with HIV, hepatitis B (HBV), or hepatitis C (HCV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a registry that collects information from people with fibrodysplasia ossificans progressiva (FOP). It helps researchers better understand the condition and use that knowledge for future studies that could lead to better care.
This trial is for people with FOP who have severe, frequent flare-ups. It follows those who are already starting an anti-IL1 medication (like anakinra) to see if it helps reduce flares and improve symptoms.
This study tests whether garetosmab, a new medication, can slow or stop abnormal bone formation in children with FOP (a rare condition where muscle and connective tissue gradually turn into bone). The goal is to help young people with FOP move better and have fewer joint limitations.
This study tracks the long-term safety and how well palovarotene works in people with FOP who are already taking it as part of their regular care. By joining, you help doctors learn more about the medicine over time.
This trial tests a new medicine called HSK44459 for people with progressive pulmonary fibrosis (PPF). It aims to see if the drug can help slow lung damage and improve breathing. You may join if you are not taking certain other fibrosis drugs or have been on a stable dose for at least 12 weeks.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
Hear when a new Fibrodysplasia Ossificans Progressiva (FOP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.